Showing 5401-5410 of 10107 results for "".
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- Opzelura Cream Safely Eases AD in Young Kidshttps://practicaldermatology.com/news/opzelura-cream-safely-eases-ad-in-young-kids/2461857/Incyte’s ruxolitinib cream (Opzelura) cleared skin in significantly more kids with atopic dermatitis (AD) than a nonmedicated topical control, a new study shows. The study, which included 300 kids aged ≥2 to <12, met its primary endpoint and showed signi
- Dermatologists Seeing High Rates of Hair Loss after COVID-19https://practicaldermatology.com/news/dermatologists-seeing-high-rates-of-hair-loss-after-covid-19/2461034/When Paula Diaz contracted COVID, she expected to lose her sense of smell and taste but not her hair. “I spent six days in the hospital being treated for the virus and several weeks after I came home, my hair started falling out in clumps,” says Paula, who added that s
- Study: Infection Rates in PsA Patients on Biologics Are Decreasinghttps://practicaldermatology.com/news/study-infection-rates-in-psa-patients-on-biologics-are-decreasing/2460979/Infection rates among people with psoriatic arthritis (PsA) taking biologics decreased from 2012 to 2017, according to new research presented at ACR Convergence, the American College of Rheumatology’s an
- Soliton Appoints Sean J. Shapiro as Vice President of Saleshttps://practicaldermatology.com/news/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales/2460643/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Alemtuzumab Highly Effective in CTCL Without Papular History: Analysishttps://practicaldermatology.com/news/study-alemtuzumab-highly-effective-in-ctcl-without-papular-history/2474209/A new analysis suggests the absence of papules, plaques, and tumors (PPT) in cutaneous T-cell lymphoma (CTCL) may predict favorable clinical outcomes with low dose alemtuzumab (LDA) therapy. In a retrospective cohort study
- Endocannabinoids Effective in Lupus Modelhttps://practicaldermatology.com/news/endocannabinoids-effective-in-lupus-model/2457521/Zylö Therapeutics’ patented Nanopod™ aerogel delivery technology was used to demonstrate the efficacy of endocannabinoids in a model of cutaneous lupus in a study presented last month at the meeting of the American College of Rheumatology. There is growing evidence that t
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t